India Mucormycosis Treatment (Black Fungus Drugs) Market Exhibits a Stunning Growth by 2027 with Cov

Author : Mrunal Nerkar | Published On : 17 Sep 2021

Mucormycosis (previously called as zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses. The fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma.  Mucormycosis needs to be treated with prescribed antifungal medication such as amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally.

 

Apply Here For The Sample Copy Of The Report: https://www.coherentmarketinsights.com/insight/request-sample/4444

 

India Mucormycosis Treatment (Black Fungus Drugs) Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period, owing to increasing cases of mucormycosis infection in the COVID-19 positive or in patients who have recovered from COVID-19 infection. For instance, according to the article published in the Diabetes and Metabolic Syndrome Journal: May 21, 2021, COVID-19 infection has been associated with a wide range of bacterial and fungal infections. Currently, mucormycosis infection cases are rising in the Indian population due to the presence of ideal environment in the COVID-19 patients, low oxygen, high glucose (in case of diabetes or steroid induces hyperglycemia), acidic medium (diabetic ketoacidosis and others), high iron levels, and suppressed immune system along with other comorbidities.


India Mucormycosis Treatment (Black Fungus Drugs) market is estimated to be valued at US9.1 Mn in 2021 and is expected to exhibit a CAGR of 3.5% over the forecast period (2021-2028).


Market Players are engaged in receiving license from the Indian government, in order to manufacture Amphotericin – B, an anti-fungal drug for the treatment of Black Fungus or mucormycosis. This is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.

Indian government has provided license to some of the market players, in order to manufacture anti-fungal drug, Amphotericin – B for the treatment of Mucormycosis (Black Fungus Drugs). For instance, on May 22, 2021, Indian government gave license to five manufacturers: Emcure Pharmaceuticals, Natco Pharmaceuticals, Gufic Biosciences, Alembic Pharmaceuticals, and Lyca Pharmaceuticals. These companies will start producing 111,000 vials of Amphotericin – B each month from July 2021.

 

Increasing prevalence of mucormycosis in the Indian population with comorbidities is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market

 

In India, diabetes mellitus is the most common underlying disease. For instance, according to the article published in the Microorganism Journal, on March 4, 2021, the pie chart shows the percentage of mucormycosis burden in different at-risk populations in India. According to the same source, diabetes mellitus is a common predisposing factor for the rhino-orbital-cerebral mucormycosis (ROCM) type of disease. A recent study from India reported that 77% of ROCM cases were in the diabetic population.

 

India Mucormycosis Treatment (Black Fungus Drugs) Market – Restraints

High cost of the medicines for the treatment of mucormycosis is expected to restrain growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period. For instance, the only antifungal drug, Amphotericin B is expensive and it will be difficult for the people to bear the cost. Currently the single vial of the drug is available in the market at a price of US$ 68.6 to US$ 109.9 (5,000 to 8,000 Indian rupees). Moreover the medicines have to be taken for 4 to 12 weeks, thus, many patients fail to take the treatment due to high cost. Government intervention may help in curbing the cost of the medicines.

 

India Mucormycosis Treatment (Black Fungus Drugs) Market Competitive Landscape

Major players operating in the India Mucormycosis Treatment (Black Fungus Drugs) market include Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs

 

Buy instant copy of this research report @ https://www.coherentmarketinsights.com/promo/buynow/4444

 

About Coherent Market Insights

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us

 

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com